The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
JAK inhibitors in dermatology: The promise of a new drug class
Open accessAbstract
&NA; New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–signal transducer and activator of transcription (JAK‐STAT) is an intracellular signaling pathway upon which many different proinflammatory signaling pathways converge. Numerous inflammatory dermatoses are driven by soluble inflammatory mediators, which rely on JAK‐STAT signaling, and inhibition of this pathway using JAK inhibitors might be a useful therapeutic strategy for these diseases. Growing evidence suggests that JAK inhibitors are efficacious in atopic dermatitis, alopecia areata, psoriasis, and vitiligo. Additional evidence suggests that JAK inhibition might be broadly useful in dermatology, with early reports of efficacy in several other conditions. JAK inhibitors can be administered orally or used topically and represent a promising new class of medications. The use of JAK inhibitors in dermatology is reviewed here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
STAT3 Mutations in the Hyper-IgE Syndrome
Holland, S. M., DeLeo, F. R., Elloumi, H. Z., Hsu, A. P., Uzel, G., Brodsky, N., Freeman, A. F., Demidowich, A., Davis, J., Turner, M. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073687 · Cited by 1,221
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Xing, L., Dai, Z., Jabbari, A., Cerise, J. E., Higgins, C. A., Gong, W., de Jong, A., Harel, S., DeStefano, G. M., Rothman, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3645 · Cited by 987
Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)
Macchi, P., Villa, A., Giliani, S., Sacco, M. G., Frattini, A., Porta, F., Ugazio, A. G., Johnston, J. A., Candotti, F., O'Sheai, J. J., et al. (1995) · Nature · doi:10.1038/377065a0 · Cited by 877
Teng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J.-L., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 873
Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development
Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L., Aman, M. J., Migone, T.-S., Noguchi, M., Markert, M. L., Buckley, R. H., et al. (1995) · Science · doi:10.1126/science.270.5237.797 · Cited by 803
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Ghoreschi, K., Jesson, M. I., Li, X., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 645
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Changelian, P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., et al. (2003) · Science · doi:10.1126/science.1087061 · Cited by 607
Clark, J. D., Flanagan, M. E., & Telliez, J.-B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 601
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.212 · Cited by 539
Rashighi, M., Agarwal, P., Richmond, J. M., Harris, T. H., Dresser, K., Su, M.-W., Zhou, Y., Deng, A., Hunter, C. A., Luster, A. D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007811 · Cited by 518
Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches
Leung, D. Y. M., & Guttman-Yassky, E. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.008 · Cited by 474
Genomic landscape of cutaneous T cell lymphoma
Choi, J., Goh, G., Walradt, T., Hong, B. S., Bunick, C. G., Chen, K., Bjornson, R. D., Maman, Y., Wang, T., Tordoff, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3356 · Cited by 428
Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
Bissonnette, R., Papp, K. A., Poulin, Y., Gooderham, M., Raman, M., Mallbris, L., Wang, C., Purohit, V., Mamolo, C., Papacharalambous, J., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14871 · Cited by 420
Bachelez, H., van de Kerkhof, P. C. M., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.-H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62113-9 · Cited by 410
Harris, J. E., Harris, T. H., Weninger, W., John Wherry, E., Hunter, C. A., & Turka, L. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.463 · Cited by 389
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C. G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89776 · Cited by 355
Self-citationHerpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Winthrop, K. L., Yamanaka, H., Valdez, H., Mortensen, E., Chew, R., Krishnaswami, S., Kawabata, T., & Riese, R. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38745 · Cited by 353
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Liu, L. Y., Craiglow, B. G., Dai, F., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.09.007 · Cited by 349
Self-citationVerstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C. B., Silver, R. T., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.115840 · Cited by 334
Papp, K. A., Menter, M. A., Abe, M., Elewski, B., Feldman, S. R., Gottlieb, A. B., Langley, R., Luger, T., Thaci, D., Buonanno, M., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14018 · Cited by 327
Bao, L., Zhang, H., & Chan, L. S. (2013) · JAK-STAT · doi:10.4161/jkst.24137 · Cited by 320
Takatsu, K., & Nakajima, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.001 · Cited by 320
Familial chilblain lupus due to a gain-of-function mutation in STING
König, N., Fiehn, C., Wolf, C., Schuster, M., Cura Costa, E., Tüngler, V., Alvarez, H. A., Chara, O., Engel, K., Goldbach-Mansky, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209841 · Cited by 308
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Anzengruber, F., Maul, J.-T., Kamarachev, J., Trüeb, R. M., French, L. E., & Navarini, A. A. (2016) · Case Reports in Dermatology · doi:10.1159/000445182 · Cited by 304
Wollenhaupt, J., Silverfield, J., Lee, E. B., Curtis, J. R., Wood, S. P., Soma, K., Nduaka, C. I., Benda, B., Gruben, D., Nakamura, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130683 · Cited by 301
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., Furniss, M., Vaughan, R., Christiano, A. M., & Clynes, R. (2016) · JCI Insight · doi:10.1172/jci.insight.89790 · Cited by 297
Gonzales, A. J., Bowman, J. W., Fici, G. J., Zhang, M., Mann, D. W., & Mitton‐Fry, M. (2014) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12101 · Cited by 264
Papp, K. A., Menter, M. A., Raman, M., Disch, D., Schlichting, D. E., Gaich, C., Macias, W., Zhang, X., & Janes, J. M. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14403 · Cited by 263
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy
Craiglow, B. G., & King, B. A. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1520 · Cited by 259
Self-citationAmano, W., Nakajima, S., Kunugi, H., Numata, Y., Kitoh, A., Egawa, G., Dainichi, T., Honda, T., Otsuka, A., Kimoto, Y., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.051 · Cited by 259
Frémond, M.-L., Rodero, M. P., Jeremiah, N., Belot, A., Jeziorski, E., Duffy, D., Bessis, D., Cros, G., Rice, G. I., Charbit, B., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.015 · Cited by 235
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
Jabbari, A., Dai, Z., Xing, L., Cerise, J. E., Ramot, Y., Berkun, Y., Sanchez, G. A. M., Goldbach-Mansky, R., Christiano, A. M., Clynes, R., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.015 · Cited by 233
Craiglow, B. G., & King, B. A. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.260 · Cited by 223
Self-citationTreatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Levy, L. L., Urban, J., & King, B. A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.06.045 · Cited by 216
Self-citationPorts, W. C., Khan, S., Lan, S., Lamba, M., Bolduc, C., Bissonnette, R., & Papp, K. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12266 · Cited by 204
Harris, J. E., Rashighi, M., Nguyen, N., Jabbari, A., Ulerio, G., Clynes, R., Christiano, A. M., & Mackay-Wiggan, J. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.09.073 · Cited by 199
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
Winthrop, K. L., Silverfield, J., Racewicz, A., Neal, J., Lee, E. B., Hrycaj, P., Gomez-Reino, J., Soma, K., Mebus, C., Wilkinson, B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207191 · Cited by 196
JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases
Alves de Medeiros, A. K., Speeckaert, R., Desmet, E., Van Gele, M., De Schepper, S., & Lambert, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164080 · Cited by 184
Tofacitinib for the treatment of alopecia areata and variants in adolescents
Craiglow, B. G., Liu, L. Y., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.09.006 · Cited by 179
Self-citationCohen, S., Radominski, S. C., Gomez‐Reino, J. J., Wang, L., Krishnaswami, S., Wood, S. P., Soma, K., Nduaka, C. I., Kwok, K., Valdez, H., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38779 · Cited by 173
Higgins, E., Al Shehri, T., McAleer, M. A., Conlon, N., Feighery, C., Lilic, D., & Irvine, A. D. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1867 · Cited by 173
Curtis, J. R., Lee, E. B., Kaplan, I. V., Kwok, K., Geier, J., Benda, B., Soma, K., Wang, L., & Riese, R. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205847 · Cited by 170
Vincenti, F., Tedesco Silva, H., Busque, S., O’Connell, P., Friedewald, J., Cibrik, D., Budde, K., Yoshida, A., Cohney, S., Weimar, W., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04127.x · Cited by 168
Al-Ali, H. K., Griesshammer, M., le Coutre, P., Waller, C. F., Liberati, A. M., Schafhausen, P., Tavares, R., Giraldo, P., Foltz, L., Raanani, P., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.143677 · Cited by 164
Verstovsek, S., Vannucchi, A. M., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Kirito, K., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.143644 · Cited by 162
Souto, A., Salgado, E., Maneiro, J. R., Mera, A., Carmona, L., & Gómez‐Reino, J. J. (2015) · Arthritis & Rheumatology · doi:10.1002/art.38894 · Cited by 160
Papp, K. A., Krueger, J. G., Feldman, S. R., Langley, R. G. B., Thaçi, D., Torii, H., Tyring, S. K., Wolk, R. A., Gardner, A., Mebus, C., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.01.013 · Cited by 157
Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
Hornung, T., Janzen, V., Heidgen, F.-J., Wolf, D. G. F., Bieber, T. R. M., & Wenzel, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1412997 · Cited by 156
Cosgrove, S. B., Wren, J. A., Cleaver, D. M., Walsh, K. A., Follis, S. L., King, V. I., Tena, J., & Stegemann, M. R. (2013) · Veterinary Dermatology · doi:10.1111/vde.12088 · Cited by 155
Busque, S., Leventhal, J. R., Brennan, D. C., Steinberg, S., Klintmalm, G. B. G., Shah, T., Mulgaonkar, S., Bromberg, J. S., Vincenti, F., Hariharan, S., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02720.x · Cited by 154
Yamanaka, H., Tanaka, Y., Takeuchi, T., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0932-2 · Cited by 154
Takeuchi, T., Tanaka, Y., Iwasaki, M., Ishikura, H., Saeki, S., & Kaneko, Y. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208279 · Cited by 152
Charles‐Schoeman, C., Wicker, P. A., González-Gay, M. Á., Boy, M. G., Zuckerman, A. L., Soma, K., Geier, J. L., Kwok, K. K., & Riese, R. J. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.05.014 · Cited by 146
Janus kinase inhibitors for rheumatoid arthritis
Yamaoka, K. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.03.006 · Cited by 142
Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis
Kurtzman, D. J. B., Wright, N. A., Lin, J., Femia, A. N., Merola, J. F., Patel, M., & Vleugels, R. A. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.0866 · Cited by 133
Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation
Fridman, J. S., Scherle, P., Collins, R. J., Burn, T. C., Neilan, C. L., Hertel, D., Contel, N. R., Haley, P., Thomas, B. A., Shi, J. G., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.140 · Cited by 117
Topical Ruxolitinib for the Treatment of Alopecia Universalis
Craiglow, B. G., Tavares, D., & King, B. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.4445 · Cited by 115
Self-citationGilhar, A., Schrum, A. G., Etzioni, A., Waldmann, H., & Paus, R. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.03.008 · Cited by 113
Works, M. G., Yin, F., Yin, C., Yiu, Y. Y., Shew, K., Tran, T.-T., Dunlap, N., Lam, J. S., Mitchell, T. J., Reader, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400205 · Cited by 102
Papp, K. A., Bissonnette, R., Gooderham, M., Feldman, S. R., Iversen, L., Soung, J., Draelos, Z. D., Mamolo, C. M., Purohit, V. S., Wang, C., et al. (2016) · BMC Dermatology · doi:10.1186/s12895-016-0051-4 · Cited by 101
Kudlacz, E. M., Conklyn, M. J., Andresen, C. J., Whitney‐Pickett, C., & Changelian, P. S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.12.024 · Cited by 96
Mesa, R. A., Verstovšek, S., Gupta, V. K., Mascarenhas, J. O., Atallah, E. L., Burn, T. C., Sun, W. Y., Sandor, V. A., & Gotlib, J. R. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.12.008 · Cited by 91
Farmer, L. J., Ledeboer, M. W., Hoock, T. C., Arnost, M. J., Bethiel, R. S., Bennani, Y. L., Black, J., Brummel, C. L., Chakilam, A. R., Dorsch, W. A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00301 · Cited by 91
JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus
Wenzel, J., van Holt, N., Maier, J., Vonnahme, M., Bieber, T. R. M., & Wolf, D. G. F. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.02.015 · Cited by 86
Ludbrook, V. J., Hicks, K. J., Hanrott, K., Patel, J., Binks, M. H., Wyres, M. R., Watson, J., Wilson, P., Simeoni, M., Schifano, L. A., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14399 · Cited by 86
Mößner, R., Diering, N., Bader, O., Forkel, S., Overbeck, T. R., Groß, U., Grimbacher, B., Schön, M. P., & Buhl, T. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw020 · Cited by 85
Bissonnette, R., Luchi, M., Fidelus-Gort, R., Jackson, S., Zhang, H., Flores, R., Newton, R. C., Scherle, P., Yeleswaram, S., Chen, X., et al. (2016) · Journal of Dermatological Treatment · doi:10.3109/09546634.2015.1115819 · Cited by 84
Tyk2 is a therapeutic target for psoriasis-like skin inflammation
Ishizaki, M., Muromoto, R., Akimoto, T., Sekine, Y., Kon, S., Diwan, M., Maeda, H., Togi, S., Shimoda, K., Oritani, K., et al. (2013) · International Immunology · doi:10.1093/intimm/dxt062 · Cited by 83
He, Y., Wong, A. Y. S., Chan, E. W., Lau, W. C. Y., Man, K. K. C., Chui, C. S. L., Worsley, A. J., & Wong, I. C. K. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-298 · Cited by 79
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis
Yi, C. A., Tam, C. S. L., & Verstovšek, S. (2015) · Future Oncology · doi:10.2217/fon.14.272 · Cited by 79
Jabbari, A., Nguyen, N. M. T., Cerise, J. E., Ulerio, G., de Jong, A., Clynes, R., Christiano, A. M., & Mackay-Wiggan, J. M. (2016) · Experimental Dermatology · doi:10.1111/exd.13060 · Cited by 79
King, B., Lee, A. I., & Choi, J. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.10.044 · Cited by 78
Self-citationWalker, S. R., Wang, C., Walradt, T. J., Hong, B. S., Tanner, J. R., Levinsohn, J. L., Goh, G., Subtil, A., Lessin, S. R., Heymann, W. R., et al. (2015) · Blood · doi:10.1182/blood-2015-06-654277 · Cited by 76
Self-citationA case of refractory dermatomyositis responsive to tofacitinib
Paik, J. J., & Christopher‐Stine, L. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.08.009 · Cited by 73
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
Punwani, N. G., Burn, T. C., Scherle, P., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13994 · Cited by 69
Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside
Damsky, W., & Choi, J. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0410-8 · Cited by 65
Self-citationRuxolitinib‐induced reversal of alopecia universalis in a patient with essential thrombocythemia
Pieri, L., Guglielmelli, P., & Vannucchi, A. M. (2014) · American Journal of Hematology · doi:10.1002/ajh.23871 · Cited by 63
Efficacy of tofacitinib in treatment of alopecia universalis in two patients
Gupta, A., Carviel, J., & Abramovits, W. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13598 · Cited by 58
Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients
Vincenti, F. G., Junior, H. T. S., Busque, S., O’Connell, P. J., Russ, G. R., Budde, K., Yoshida, A., Tortorici, M. A., Lamba, M., Lawendy, N., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13181 · Cited by 54
Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro
Wang, S.-P., Iwata, S., Nakayamada, S., Sakata, K., Yamaoka, K., & Tanaka, Y. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205615 · Cited by 49
Tofacitinib for polyarteritis nodosa: a tailored therapy
Rimar, D., Alpert, A., Starosvetsky, E., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209330 · Cited by 46
Wu, J. J., Strober, B. E., Hansen, P. R., Ahlehoff, O., Egeberg, A., Qureshi, A. A., Robertson, D. H., Valdez, H., Tan, H., & Wolk, R. A. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.06.012 · Cited by 45
Lernia, V. G. D., & Bardazzi, F. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s82599 · Cited by 42
Koga, T., Sato, T., Umeda, M., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.10.003 · Cited by 37
Fujii, Y., & Sengoku, T. (2013) · Pharmacology · doi:10.1159/000347184 · Cited by 30
Safety evaluation of ruxolitinib for treating myelofibrosis
Galli, S., McLornan, D. P., & Harrison, C. N. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.916273 · Cited by 28
Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis
Yacoub, A., & Prochaska, L. (2016) · Biomarker Research · doi:10.1186/s40364-016-0056-5 · Cited by 28
Clinical perspectives and murine models of lichenoid tissue reaction/interface dermatitis
Okiyama, N., & Fujimoto, M. (2015) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2015.03.001 · Cited by 25
Damsky, W., & King, B. (2016) · JAAD Case Reports · doi:10.1016/j.jdcr.2016.10.009 · Cited by 20
Self-citationSafety considerations when treating myelofibrosis
O’Sullivan, J. M., McLornan, D. P., & Harrison, C. N. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1185414 · Cited by 12
Cited by
Karki, R., Sharma, B. R., Tuladhar, S., Williams, E. P., Zalduondo, L., Samir, P., Zheng, M., Sundaram, B., Banoth, B., Malireddi, R. K. S., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.025 · Cited by 1,734
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Vitiligo: Mechanisms of Pathogenesis and Treatment
Frisoli, M. L., Essien, K., & Harris, J. E. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100919-023531 · Cited by 618
Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., Thaçi, D., Chu, C.-Y., Hong, H. C.-H., Katoh, N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00588-2 · Cited by 583
Two Phase 3 Trials of Baricitinib for Alopecia Areata
King, B., Ohyama, M., Kwon, O., Zlotogorski, A., Ko, J., Mesinkovska, N. A., Hordinsky, M., Dutronc, Y., Wu, W.-S., McCollam, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2110343 · Cited by 506
Self-citation
Metadata
- Authors
- Damsky, W., & King, B. A.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 76
- Issue
- 4
- Pages
- 736-744
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2580870032
- Cited by
- 530
- References
- 93
- FWCI
- 18.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.